Dual Immunotherapy Improves Response Rates in Gynecologic Clear Cell Cancers

June 4, 2024 9:00 am

by Wayne Kuznar

CHICAGO — Clinical activity and survival outcomes improved with the addition of ipilimumab (Yervoy) to nivolumab (Opdivo) in patients with ovarian or other gynecologic clear cell carcinomas, according to results from the non-comparative phase II BrUOG 354 … Read more

No Benefit to Adding Atezolizumab to Chemo/Bevacizumab for Ovarian Cancer

June 2, 2024 9:00 am

by Silas Inman

The addition of atezolizumab (Tecentriq) to single-agent non–platinum-based chemotherapy and bevacizumab (Avastin) did not provide any additional benefits for patients with recurrent ovarian cancer, according to the final analysis of the phase 3 AGO-OVAR 2.29/ENGOT-ov34 study (NCT03353831) … Read more

Advanced Ovarian Cancer: Can Lymphadenectomy Be Avoided for Some Patients?

June 2, 2024 9:00 am

by The ASCO Post Staff

Some people with advanced epithelial ovarian cancer may safely avoid having their lymph nodes removed during surgery without it impacting their survival outcomes, helping to reduce the risk of postoperative complications. This research was presented … Read more

Estrogen-Only Hormone Therapy Linked to Increased Gynecologic Cancer Risk, But Estrogen-Progestin Combination Therapy Lowers It

June 1, 2024 9:00 am

by Aaron Tallent

Key Points:

  • Hormone replacement therapy (HRT) can reduce bothersome symptoms of menopause, but there is concern it may increase the incidence of certain cancers.
  • An analysis from the Women’s Health Initiative shows that estrogen-only HRT may increase
Read more

Sydney researchers find differences in ovarian cancer risk factors by racial and ethnic groups

May 31, 2024 9:00 am

Researchers conducted an international study of more than 11,000 ovarian cancer cases found selected ovarian cancer risk factors vary for women of different racial and ethnic backgrounds.

Led by Dr Melissa Merritt and Dr Nicola Meagher from the Daffodil Centre … Read more

For some endometriosis-related ovarian cancers, timing is everything

May 28, 2024 9:00 am

by Van Andel Research Institute

Two types of endometriosis-related ovarian cancer arise from the same cells but likely at different stages of the menstrual cycle—a nuance that significantly influences treatment response, reports a recent study led by Van Andel Institute … Read more

Sister Study Cohorts Shows Association of Gential Talc Use and Ovarian Cancer

May 23, 2024 9:00 am

by Ariana Pelosci

Results of a recent study published in the Journal of Clinical Oncology highlighted the association of ovarian cancer with talcum powder (talc) use.1 The findings were from an extensive analysis of the Sister Study cohort.… Read more

New Approach May Help People with Cancer Better Manage Depression, Pain, and Fatigue

May 14, 2024 9:00 am

Clearity offers emotional support to individuals with ovarian cancer through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC Counselors may be Read more

Yoga shows ‘most improvement’ in restoring brain health in long-term cancer survivors, Northeastern researcher says

May 10, 2024 9:00 am

by Cynthia McCormick Hibbert

For too many cancer survivors, life after treatment is fraught with a decline in cognitive function known as “chemo brain.”

newly published study by a Northeastern professor says that yoga might hold the key to … Read more

LGBTQ+ Voices: Listening to Sexual and Gender Minority People Affected by Cancer

May 1, 2024 9:00 am

by Edward Winstead

This story has an accompanying Q&A with Dr. Gwendolyn Quinn, Ph.D., of the New York University Perlmutter Cancer Center, on some of the challenges faced by LGBTQ+ people with cancer and ways to address them.

After surgery … Read more

New FDA Guidance Looks to Improve Clinical Trial Enrollment and Diversity

April 30, 2024 9:00 am

by Sabrina Serani

The FDA announced new guidance to expand eligibility criteria with the goal of improving participation and diversity in oncology clinical trials.These 3 areas of change include laboratory values, washout periods, and performance status.

While the FDA notes … Read more

AI partners with liquid biopsy for ‘robust’ identification of women with ovarian cancer

April 10, 2024 9:00 am

by Josh Friedman

Key takeaways:

  • AI-analyzed fragmentomes and protein biomarkers better distinguished women with ovarian cancer in screening.
  • Liquid biopsy assay outperformed CA125 analysis alone.

An artificial intelligence-driven algorithm used a novel liquid biopsy assay to differentiate women with ovarian … Read more

Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancers

— About half of patients responded, duration of response as long as 19 months in three trials

April 5, 2024 9:00 am

By Charles Bankhead

The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.

The action represents the first tumor-agnostic approval for an antibody-drug conjugate targeting HER2-positive tumors. According … Read more

Stress-Induced Immune Changes May Help Cancer Spread

April 2, 2024 9:00 am

Clearity’s Perspective: This article highlights the importance of learning ways to cope with and manage stress after an ovarian cancer diagnosis. The study, performed only on mice, suggests that there may be a link between overproduction of stress hormones and Read more

Women’s Cancers: Clinicians Research, Advise on Sexual Dysfunction

March 29, 2024 9:00 am

By Heidi Splete

Many women with cancer want advice for managing sexual function issues, and clinicians are tuning in, new studies suggest.

Decreased sexual function is a side effect of many types of cancer, notably uterine, cervical, ovarian, and breast … Read more

Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC

March 22, 2024 9:00 am

By Ryan Scott

Patients who are heavily pretreated with recurrent low-grade serous ovarian cancer (LGSOC) had high response rates, regardless of the number of prior lines of therapy received, when treated with avutometinib (previously VS-6766) plus defactinib, according to data … Read more

ctDNA Offers Potential Biomarker for PARP Inhibitor Maintenance Therapy in Epithelial Ovarian Cancer

March 20, 2024 9:00 am

Clearity’s Perspective: At the SGO meeting several presentations described how circulating tumor DNA (ctDNA) may be a new, personalized, sensitive tool to help evaluate treatment de-escalation, monitor minimal residual disease (MRD), and track treatment response in ovarian cancer. The application Read more

Rezatapopt Shows Preliminary Efficacy in TP53 Y220C–Mutated Advanced Ovarian Cancer

March 19, 2024 9:00 am

By Kristi Rosa

Rezatapopt (PC14586) elicited responses with a favorable toxicity profile in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations, according to data from the phase 1/2 PYNNACLE study (NCT04585750) presented at the 2024 SGO Annual … Read more

New microbiome insights could help boost immunotherapy for a range of rare cancers

March 1, 2024 9:00 am

Clearity’s Perspective: Previous research in different types of cancer has suggested that there is a relationship between a cancer patient’s gut microbiota (microorganisms that live in the digestive tract) composition and the response to immune checkpoint inhibitor therapy; however,

Read more

Cancer Prevention Strategies Linked to Mortality Reduction in BRCA Carriers

February 29, 2024 9:00 am

By Mike Basset

Risk management strategies including bilateral salpingo-oophorectomy (BSO) for ovarian cancer and MRI surveillance for breast cancer were associated with a significant reduction in mortality for women with BRCA1/2 sequence variations, according to results from two cohort studies … Read more